Method for detection and determination of human serum albumin

• US 5,182,214 A
• Filed: 07/20/1990
• Issued: 01/26/1993
• Est. Priority Date: 08/17/1989
• Status: Expired due to Fees

• Current Assignee: Manfred Kessler, Otto S. Wolfbeis
• Original Assignee: Manfred Kessler, Otto S. Wolfbeis
• Inventors: Wolfbeis, Otto S., Kessler, Manfred
• Primary Examiner(s): Housel, James C.
• Assistant Examiner(s): REDDING, DAVID A
• Application Number:
  US07/556,268
• Time in Patent Office: 921 Days
• Field of Search: 436/86, 436/87, 436/88, 436/165, 436/172, 436/164
• US Class Current: 436/88
• CPC Class Codes: G01N 31/22 using chemical indicators G01N31/02 takes precedence
• CPC Class Codes: G01N 33/52 Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper and including single- and multilayer analytical elements immunological elements G01N33/54386; involving labelled immunochemicals G01N33/58; for haemoglobin or occult blood G01N33/72
• CPC Class Codes: G01N 33/6839 involving dyes, e.g. Coomassie blue, bromcresol green

Abstract

An optical method for quantitative determination of human serum albumin (HSA) in biological liquids such as urine is based on the observation that the absorption and fluorescence of certain anionic cyanine dyes possessing a terminal cyano group and having the general formula ##STR1## are strongly affected by HSA. This approach is distinctly more sensitive than existing techniques, allowing the detection and quantization of micro-albuminuria (i.e. detection of HSA in the 1-10 mg per liter concentration range) at costs which are distinctly lower than those for existing immunological assays. It is also much more specific for HSA than existing assays based on dye binding. Because the dyes has long wave absorptions and emissions, use can be made of electro-optical components based on semiconductor technology.

Claims

1. A method for optical detection and quantitative determination of human serum albumin or HSA in biological liquids comprising the steps of

a) providing a sample of a biological liquid containing human serum albumin or HSA;

b) adding to the sample an anionic cyanine dye of general formula (1) ##STR8## where n means 0 or 1;

M⁺ is any monovalent cation;

R⁰ is cyano, aryl, or COR where R stands for alkoxy, alkyl or aryl;

R¹ is cyano, aryl, or COR where R stands for alkoxy, alkyl, or aryl;

R², R⁸ each stand for hydrogen, alkyl, or cyano;

R³, R⁵, R⁶, R⁷ each stand for hydrogen or alkyl;

R⁴ stands for hydrogen, halogen, alkyl, aryl, aryloxy, alkoxy, or NR₂ where R stands for alkyl or aryl;

R⁹ stands for cyano, aryl, COR where R stands for alkoxy, alkyl, or aryl, CO-NAB where A stands for alkyl, aryl, or carbamoyl and B stands for alkyl or aryl, hydrogen, or heterocyclyl;

R¹⁰ stands for cyano, aryl, COR where R stands for alkoxy, alkyl, or aryl, CO-NAB where A stands for alkyl, aryl or carbamoyl, and B stands for alkyl or aryl, hydrogen, or heterocyclyl;

and where at least one substituent of R⁰, R¹, R⁹ or R¹⁰ stands for cyano;

c) measuring the increase in fluorescence intensity, or the change in fluorescence polarization, or the change in fluorescence lifetime of the dye, or the change in absorption of the dye as a result of binding of HSA to the dye; and

d) relating the change in fluorescence or absorption to the actual amount of HSA in the sample.

2. A method of claim 1, wherein

n is O,

R², R⁸ each stand for hydrogen,

R³ and R⁵ each stand for an ethylene or propylene bridge,

R⁴ stands for chlorine,

R⁰, R¹, R⁹ each stand for cyano, and

R¹⁰ stands for cyano, or a substituted 2-benzoxazolyl group.

3. A method according to claim 1 wherein a helium-neon laser or a laser diode is used as the excitation light source in step c).

4. A method according to claim 1 prior to the step a) wherein the sample is first filuted or injected into a carrier stream.

5. The method of claim 1, wherein R³ and R⁵ each stand for (CH₂)₂.

6. The method of claim 1, wherein R³ and R⁵ each stand for (CH₂)₃.